Sermorelin + GHRP-6 + GHRP-2

Snapshot Sermorelin and ipamorelin are investigational peptides that stimulate endogenous growth hormone release through complementary GHRH and ghrelin receptor pathways. Preclinical and physiological data support synergistic GH pulsatility when both signaling axes are engaged, though direct combination studies remain limited. What Is Sermorelin? Sermorelin is a synthetic peptide analog of growth hormone–releasing hormone (GHRH), corresponding to the first 29 amino acids of endogenous human GHRH [1]. Sermorelin acts on the anterior pituitary and stimulates pulsatile secretion of growth hormone (GH). This preserves endogenous regulatory feedback mechanisms and the natural circadian rhythm of GH release. In research and clinical studies, sermorelin has been used as a tool to assess pituitary GH reserve and to explore age-related or functional declines in GH signaling. By activating the GHRH receptor, sermorelin promotes downstream effects on IGF-1 production, protein synthesis, and metabolic regulation [2], [3]. What Is Ipamorelin? Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue that acts primarily through the ghrelin (GHS-R1a) receptor in the pituitary and hypothalamus [4]. Unlike other GH secretagogues, ipamorelin is designed to stimulate growth hormone release with minimal impact on other pituitary hormones, such as cortisol or prolactin. Preclinical and early human studies indicate that ipamorelin promotes physiologic, pulsatile GH secretion without significantly increasing appetite or activating broad stress pathways. Because it acts through a receptor pathway distinct from GHRH, ipamorelin is investigated for its complementary role in modulating endogenous GH signaling. Sermorelin-Ipamorelin Synergy Sermorelin and ipamorelin are often grouped together because they stimulate growth hormone release through distinct, yet convergent methods in the somatotropic axis. Sermorelin activates the GHRH receptor on pituitary somatotrophs, activating cAMP/PKA signaling to promote pulsatile GH secretion [5]. Ipamorelin, by contrast, is a ghrelin receptor (GHS-R1a) agonist, which activates complementary intracellular pathways (PLC/IP3/Ca²+-linked signaling) that also facilitate GH release [6]. Complementary Mechanisms The rationale for synergy is not simply "two peptides = more GH," but rather that GHRH and ghrelin/GHS signaling amplify each other's downstream effects at the pituitary and hypothalamic level. Experimental work shows that ghrelin and growth hormone secretagogues can potentiate GHRH-driven signaling responses in model systems expressing both receptors [7]. In addition, mechanistic studies have reported receptor-level and pathway-level cross-talk between GHRH-related signaling and ghrelin receptor biology, creating a plausible basis for amplified GH pulsatility when both pathways are engaged [8]. From a systems perspective, this pairing can be framed as: Sermorelin: provides the physiologic "go" signal via the GHRH axis. Ipamorelin: supplies a parallel "gain" signal through GHS-R1a, which can increase responsiveness of somatotrophs and increase pulse amplitude. Literature-Based Evidence Direct, peer-reviewed studies that specifically test sermorelin (GHRH 1–29) combined with ipamorelin as a named pairing are limited. However, there is evidence for class-level synergy (GHRH analogs used with ghrelin/GHS receptor agonists) showing amplified GH responses compared with either pathway alone. An in vitro study examined how GHRH and growth hormone secretagogues (GHS), like ghrelin, interact at the cellular signaling level to regulate growth hormone (GH) release [7]. A heterologous cell system expressing cloned, epitope-tagged GHRH and GHS receptors were given GHRH alone, GHS or ghrelin alone, or combined receptor activation. Effects were tracked through cAMP production and pathway-specific pharmacologic inhibition. Results showed that: GHS receptor activation alone did not affect cAMP production, whereas GHRH activation typically does. Coactivation of GHRH + GHS receptors resulted in a ~2-fold increase in cAMP compared with GHRH, and dose dependent potentiation for both GHRH and GHS. Multiple peptide GHS compounds, including GHRP-6 (similar in mechanism to ipamorelin [9]) had a combined potentiation effect. The results show a selective and receptor-specific synergy between GHRH and GHS receptors, amplifying cAMP signaling beyond what GHRH alone produces. Given this in vitro evidence, the sermorelin–ipamorelin rationale is therefore best presented as mechanistic extrapolation rather than as a conclusively proven combination therapy. Dose and Ratio From a research design standpoint, a 1:1 mass ratio (5 mg + 5 mg or 10 mg + 10 mg) can be framed as aiming to engage both upstream control systems, GHRH receptor signaling and GHS-R1a signaling, without over-weighting one pathway at the expense of the other. Beyond that general rationale, the optimal ratio has not been established in the open literature and should be treated as an empirical parameter rather than a settled standard. References 1 Walker, R. F. (2006) Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin. Interv. Aging, Dove Medical Press Ltd. 1, 307–308 2 Prakash, A. and Goa, K. L. (1999) Sermorelin: A review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs, Springer Nature 12, 139–157 3 Khorram, O., Laughlin, G. A. and Yen, S. S. (1997) Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J. Clin. Endocrinol. Metab., The Endocrine Society 82, 1472–1479 4 Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., et al. (1998) Ipamorelin, the first selective growth hormone secretagogue. Eur. J. Endocrinol. 139, 552–561 5 Aitman, T. J., Rafferty, B., Coy, D., Lynch, S. S. and Clayton, R. N. (1989) Bioactivity of growth hormone releasing hormone (1-29) analogues after SC injection in man. Peptides, Elsevier BV 10, 1–4 6 Khatib, N., Gaidhane, S., Gaidhane, A. M., Khatib, M., Simkhada, P., Gode, D., et al. (2014) Ghrelin: ghrelin as a regulatory Peptide in growth hormone secretion. J. Clin. Diagn. Res., JCDR Research and Publications 8, MC13–7 7 Cunha, S. R. and Mayo, K. E. (2002) Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3’,5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology, The Endocrine Society 143, 4570–4582 8 Casanueva, F. F., Camiña, J. P., Carreira, M. C., Pazos, Y., Varga, J. L. and Schally, A. V. (2008) Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a. Proc. Natl. Acad. Sci. U. S. A., Proceedings of the National Academy of Sciences 105, 20452–20457 9 Mau, S. E., Witt, M. R., Bjerrum, O. J., Saermark, T. and Vilhardt, H. (1995) Growth hormone releasing hexapeptide (GHRP-6) activates the inositol (1,4,5)-trisphosphate/diacylglycerol pathway in rat anterior pituitary cells. J. Recept. Signal Transduct. Res., Informa UK Limited 15, 311–323

What is SS-31 peptide? SS-31 is a small, 4-amino acid, mitochondria-targeting peptide, found to have antioxidant and cell-protective effects [1]. Made up of alternating aromatic and basic amino acids, it contains a dimethyl tyrosine residue that neutralizes reactive oxygen species (ROS) and prevents lipid peroxidation [1]. Pharmacologically, SS-31 is water-soluble, stable, and resistant to enzymatic breakdown [1]. It can easily penetrate cell membranes due to its structure. It is distributed widely throughout the body, with the highest concentrations in the kidneys, and is completely excreted in urine [1]. Clinical studies show it is generally safe, with only mild side effects at the injection site, and no serious problems reported [1]. Once within cells, SS-31 rapidly accumulates in the inner mitochondrial membrane, up to 5,000 times more than in the surrounding cellular environment. Inside the mitochondria, it stabilizes cardiolipin, a critical phospholipid involved in the electron transport chain [1]. By doing so, SS-31 reduces electron leakage, preserves mitochondrial structure, and enhances ATP production [1]. Because cardiolipin damage has been implicated in various conditions such as neurodegeneration, heart failure, and mitochondrial myopathies, SS-31 has been studied as a novel therapeutic and promising candidate for conditions driven by mitochondrial dysfunction [2]. SS-31 benefits, mechanisms of action, and side effects SS-31 attaches to cardiolipin, a phospholipid found within the inner layer of the mitochondria that helps maintain structure and stability [3]. In doing so, it protects cardiolipin and supports the electron transport chain [4]. This allows SS-31 to improve ATP production and counteract the impacts of oxidative stress [4]. SS-31 also activates specific antioxidant pathways, upregulating specific proteins that help protect against oxidative stress and ferroptosis cell damage [2]. Clinical and pre clinical studies have demonstrated its protective activities in cardiac, neurological, renal, and skeletal muscle tissues [5, 6, 7, 8, 9]. In models of spinal cord injuries, it also has neuroprotective activities [10]. Mitochondrial function and apoptosis SS-31, through cardiolipin binding, preserves cristae architecture and supports efficient ATP production and electron transport [11]. As a strong antioxidant, it scavenges mitochondrial ROS to restore membrane potential and enhance the cell’s ATP generation [3]. Together, these mechanisms explain why SS-31 can maintain mitochondrial morphology, and prevent swelling and depolarization under stress conditions [12].  SS-31 upregulates SIRT1 expression, which suggests it may improve mitochondrial resilience and cellular metabolism through gene regulation [13]. Cardiolipin stabilization from SS-31 also prevents its peroxidation, reducing cytochrome C leakage and activation of apoptotic pathways [10]. SS-31 lowers caspase-3 activity, shifts specific pathways towards cell survival, and reduces DNA fragmentation to prevent apoptosis [14]. Heart health SS-31 protects and restores heart health, particularly in conditions associated with heart failure, hypertension, atherosclerosis, and decreased blood flow [15]. By binding and stabilizing within mitochondrial membranes, SS-31 lowers oxidative stress and improves energy production [16]. In models of aging hearts, it restores healthy diastolic function and lowers oxidative damage without interfering with systolic function [16]. SS-31 repairs age-related changes in important heart proteins, improving muscle relaxation and resilience [17]. In models of cardiomyopathy and heart failure, SS-31 prevents apoptosis, limits scarring and thickening of cardiac muscle, and improves overall energy efficiency [5]. This remains even when blood pressure remains high [18]. It also strengthens aerobic metabolism, helping the heart meet high energy demands [19]. Within the blood vessels, SS-31 lowers inflammation, stabilizes atherosclerotic plaques, and enhances ATP production [20]. In ischemia-reperfusion, SS-31 reduces tissue damage and speeds recovery [21]. Antioxidant and anti-inflammatory properties SS-31 can neutralize reactive oxygen species and provide protection for mitochondrial membranes [22]. By binding cardiolipin, SS-31 prevents cardiolipin peroxidation, which helps preserve mitochondrial integrity, limit cytochrome C leakage, and protect against mitochondrial dysfunction [23]. One study found SS-31 was able to prevent depletion of key antioxidant enzymes, including myeloperoxidase and superoxide dismutase, helping maintain redox balance [24]. By limiting oxidative damage, SS-31 can preserve mitochondrial energy output, limiting further ROS generation. SS-31 also has anti-inflammatory impacts, with research finding it can lower levels of TNF-α, IL-1β, and IL-6 in lung tissue. These cytokines are key mediators of inflammatory and fibrotic signaling [22]. Because high ROS amplifies profibrotic pathways, reducing ROS indirectly lowers inflammation and fibrosis. Through its impacts on myeloperoxidase, SS-31 reduces neutrophil-driven tissue injury and inflammation [22].

Snapshot Survodutide is a dual GLP-1 and glucagon receptor agonist studied for its role in integrated metabolic regulation. By combining appetite and satiety signaling with hepatic energy and lipid metabolism pathways, it has benefits on weight reduction, glycemic control, cardiometabolic risk, and fatty liver through coordinated endocrine signaling rather than single-pathway modulation. What Is Survodutide? Survodutide is a synthetic, long-acting dual-agonist peptide designed to activate both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R) [1]. This dual-receptor profile distinguishes survodutide from single-pathway incretin peptides and reflects an approach aimed at integrating energy expenditure and appetite regulation. Side Effect Profile The side-effect profile observed with survodutide in clinical research appears consistent with other peptides that engage GLP-1–based pathways, with gastrointestinal effects such as nausea and discomfort reported as the most common events [2]. These effects are dose-dependent and prominent during rapid dose escalation. Compared with GLP-1–only agonists, glucagon receptor activity introduces additional considerations related to hepatic glucose output and energy metabolism. Survodutide Benefits Weight Loss Survodutide enhances central satiety cues, slows gastric emptying, and reduces meal size, contributing to weight loss. A Phase 2 RCT evaluated the safety, tolerability, and efficacy of survodutide in 387 adults overweight or obese without diabetes. Participants were randomized to once-weekly subcutaneous survodutide (0.6 mg, 2.4 mg, 3.6 mg, or 4.8 mg) or placebo for 46 weeks (20 weeks dose escalation, 26 weeks maintenance) [3]. Survodutide administration resulted in: Statistically significant, dose-dependent weight loss across all levels (p < 0.05). Statistically significant, dose-dependent waist circumference decreases across all levels (p < 0.05). Statistically significant, dose-dependent blood pressure drops at 2.4 mg and higher (p < 0.05). Mild adverse events in 91% of participants versus 75% of placebo. Results can be visualized below: Parameter Placebo Survodutide doses 0.6 mg 2.4 mg 3.6 mg 4.8 mg Bodyweight (%) -2.8 -6.2 -12.5 -13.2 -14.9 Waist Circumference (cm) -4.0 -8.3 -15.0 -15.0 -16.0 Systolic Blood Pressure (mmHg) -2.5 -6.2 -8.1 -8.7 -8.6 Diastolic Blood Pressure (mmHg) -1.9 -3.3 -4.4 -4.3 -4.8 The trial demonstrates that dual GLP-1/glucagon receptor agonism produces clinically meaningful, dose-dependent weight loss with an acceptable tolerability profile. Cardiometabolic Benefits and Glycemic Control Currently, clinical trials are underway to investigate survodutide’s effects on cardiovascular outcomes in patients with cardiovascular or kidney disease [4]. However, the peptide has been well studied in its potential for glycemic control. A Phase 2 RCT evaluated the dose response effects of survodutide on glycemic control and body weight in 413 adults with type 2 diabetes receiving background metformin therapy [5]. Participants were randomized to once or twice-weekly survodutide at varying doses, placebo, or open-label semaglutide (1.0 mg once weekly) for 16 weeks. Survodutide resulted in: Clinically significant reductions in HbA1c across all dose groups, and comparable reductions to semaglutide at low doses. Mild gastrointestinal side effects at a higher rate (77.8%) than placebo (52.5%) or semaglutide (52.0%). Slower dose escalation helps mitigate dose-related gastrointestinal effects. Results can be visualized below: Parameter Placebo Survodutide weekly doses 0.3 mg 1x 0.9 mg 1x 1.8 mg 1x 2.7 mg 1x 1.2 mg 2x 1.8 mg 2x HbA1C (mmol) -1.62 -9.92 -15.95 -18.72 -17.01 -17.84 -18.38 Bodyweight Reduction > 5% - 8% 38% 42.3% 46% 56.9% 57.1% Bodyweight Reduction > 10% - 2% 6% 13.5% 16.0% 25.5% 34.7% The findings support further development of dual GLP-1/glucagon receptor agonism for metabolic disease management. Fatty Liver Fatty liver disease is closely linked to insulin resistance, excess caloric intake, and impaired lipid oxidation, pathways directly influenced by survodutide. A Phase 2 RCT evaluated the safety and efficacy of survodutide in 293 adults with biopsy-confirmed MASH and liver fibrosis. Participants were randomized to receive once-weekly subcutaneous survodutide (2.4 mg, 4.8 mg, or 6.0 mg) or placebo over 48 weeks, consisting of a 24-week dose-escalation phase followed by a 24-week maintenance phase [2]. Results showed that survodutide: Histologically improved MASH without worsening of fibrosis across all levels (p < 0.001) Reduced ≥30% of liver fat in 67% of participants, (vs. 14% with placebo). Improved fibrosis by at least one stage in 36% of participants (vs. 22% with placebo). Results by dosage can be visualized below: Parameter Placebo Survodutide doses (once weekly) 2.4 mg 4.8 mg 6.0 mg Histological Improvement (%) 14 47 62 43 Fibrosis Improvement by One Stage or more (%) 22 34 36 34 GI adverse events were common: Nausea (66%) Diarrhea (49%) Vomiting (41%) Serious adverse events occurred at similar rates in the survodutide and placebo groups. Dual GLP-1/glucagon receptor agonism with survodutide significantly improved features of MASH and reduced liver fat, prompting larger phase 3 trials for liver-related metabolic disease. References 1 Wharton, S., le Roux, C. W., Kosiborod, M. N., Platz, E., Brueckmann, M., Jastreboff, A. M., et al. (2025) Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZETM-1 and -2). Obesity (Silver Spring), Wiley 33, 67–77 2 Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., et al. (2024) A phase 2 randomized trial of survodutide in MASH and fibrosis. N. Engl. J. Med., Massachusetts Medical Society 391, 311–319 3 le Roux, C. W., Steen, O., Lucas, K. J., Startseva, E., Unseld, A. and Hennige, A. M. (2024) Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol., Elsevier BV 12, 162–173 4 Kosiborod, M. N., Platz, E., Wharton, S., le Roux, C. W., Brueckmann, M., Ajaz Hussain, S., et al. (2024) Survodutide for the treatment of obesity: Rationale and design of the SYNCHRONIZE cardiovascular outcomes trial. JACC Heart Fail., Elsevier BV 12, 2101–2109 5 Blüher, M., Rosenstock, J., Hoefler, J., Manuel, R. and Hennige, A. M. (2024) Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia, Springer Science and Business Media LLC 67, 470–482